EHA Preview: ASCO Overlap Gives Smaller Companies Chance To Shine

Cargo Therapeutics has got an early boost from its abstract to be presented the European meeting, while Shattuck has suffered on safety doubts for its CD47 inhibitor.

Share price up and down
Congresses like EHA give early-stage companies a chance to shine, but uncertain data releases can cause major share price swings • Source: Shutterstock

Smaller biopharma companies will have a chance to shine at this year’s European Hematology Association congress, with Cargo Therapeutics and Kymera among those already picked out by analysts as ones to watch ahead of the meeting next month.

Key Takeaways
  • Many big pharma datasets at EHA follow on from ASCO presentations – which should give smaller companies room to promote their results

That is because while numerous major studies are due to be presented by big pharma at the EHA in Madrid,...

More from Clinical Trials

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

More from R&D

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.